Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 14/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.55 |
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11870407 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL6926435 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL6927655 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11870393 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11866992 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL17075565 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL17075566 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL2091563 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL2091575 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11872484 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | claimed |
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | MIRECA MEDICINES GMBH (DE) | 2019-06-18 | — | — | US | claimed |
| EP-2398500-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2 BBB MEDICINES B V (NL) | 2019-03-13 | — | — | EP | claimed |
| EP-3395372-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2-BBB Medicines B.V. (NL) | 2018-10-31 | — | — | EP | claimed |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | claimed |
| EP-3270889-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | Mireca Medicines GmbH (DE) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146669-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2016-09-22 | — | — | WO | claimed |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2014-08-14 | — | — | US | claimed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| US-20060148020-A1 | Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer | MANNERVIK, BENGT (SE) | 2006-07-06 | — | — | US | claimed |
| EP-1567645-A1 | INHIBITORS OF GST A3-3 AND GST A1-1 FOR THE TREATMENT OF CANCER | BIOVITRUM AB (SE) | 2005-08-31 | — | — | EP | claimed |
| WO-2004048577-A1 | INHIBITORS OF GST A3-3 AND GST A1-1 FOR THE TREATMENT OF CANCER | BIOVITRUM AB (SE) | 2004-06-10 | — | — | WO | claimed |
| EP-0645397-B1 | Glutathione analogs and paralog panels comprising glutathione mimics | TERRAPIN TECH INC (US) | 1998-09-09 | — | — | EP | claimed |
| US-12617771-B2 | Diphenylpyrazole compound, and preparation method therefor and application thereof | NORTHWEST A&F UNIVERSITY (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12503636-B2 | Corrosion inhibitor composition for wet sour crude | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-12-23 | — | — | US | disclosed |
| EP-0356838-A2 | Chromatographic stationary supports | AT BIOCHEM (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0256223-A1 | Herbicide tolerant plants containing a glutathione-S-transferase gene | CIBA-GEIGY AG (CH) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 64/4885NOD1 3854/4885 |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885NOD1 3457/4885 |
| US-20060148020-A1 | Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer | GSTA1, GSTK1, GSTM1 | PTGS1 35/4885GSTK1 2/4885NOD1 3238/4885 |
| US-12617771-B2 | Diphenylpyrazole compound, and preparation method therefor and application thereof | GSTP1, GSTO1, GSTA1 | PTGS1 310/4885GSTK1 15/4885NOD1 986/4885 |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 71/4885NOD1 3852/4885 |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885NOD1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.